00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
20:24 , Apr 5, 2019 |  BC Week In Review  |  Clinical News

Proteon's vonapanitase misses another Phase III

Proteon said vonapanitase missed the co-primary endpoints in the Phase III PATENCY-2 trial to improve vascular access in chronic kidney disease (CKD) patients undergoing surgery for radiocephalic arteriovenous fistula (AVF) creation for hemodialysis. Compared with...
21:02 , Dec 14, 2018 |  BC Week In Review  |  Company News

Mereo, OncoMed announce merger

Mereo BioPharma Group plc (LSE:MPH) announced a merger with OncoMed Pharmaceuticals Inc. (NASDAQ:OMED); the resulting entity will focus on development of Mereo's orphan disease pipeline and will be listed on London Stock Exchange and NASDAQ....
11:26 , Sep 28, 2018 |  BC Extra  |  Preclinical News

Two strategies block immune-mediated metastases in mice

Cold Spring Harbor Laboratory researchers and a team from two Italian institutions have published two different strategies to fight immune-mediated lung metastases. Dormant cancer cells can persist for years before awakening and proliferating, leading to...
00:00 , Aug 11, 2018 |  BioCentury  |  Product Development

Exacerbation management

Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1. The company is...
18:53 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

NovaBiotics' oral Lynovex improves outcomes in Phase II for CF

NovaBiotics Ltd. (Aberdeen, U.K.) said oral Lynovex cysteamine (formerly NM001) as an adjunct to standard of care (SOC) significantly improved health-related questionnaire scores and reduced respiratory symptom severity compared with SOC alone in the Phase...
00:55 , Feb 14, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Aneurysm Mouse studies suggest the CysLT1 inhibitor Singulair montelukast could help treat abdominal aortic aneurysm (AAA). In a mouse model of calcium chloride-induced AAA, Singulair decreased aortic dilation compared with no treatment. In a...
02:53 , Dec 8, 2017 |  BC Week In Review  |  Company News

Mero licenses AAT deficiency candidate from AstraZeneca

AstraZeneca plc (LSE:AZN; NYSE:AZN) granted Mereo BioPharma Group plc (LSE:MPH) an exclusive license and option to acquire AZD9668, an oral inhibitor of neutrophil elastase (ELANE; NE; HLE) which is in development to treat alpha-1 antitrypsin...
00:28 , Oct 20, 2017 |  BC Week In Review  |  Financial News

Antabio raises EUR7.3M series A

Antabio S.A.S. (Labege, France) said it raised €7.3 million ($8.6 million) on Oct. 16 in a series A round from iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion, and private individuals. Antabio is developing inhibitors...
22:13 , Oct 16, 2017 |  BC Extra  |  Financial News

Antabio raises €7.3M in series A

Antabio S.A.S. (Labege, France) said it raised €7.3 million ($8.6 million) in a series A round from iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion, and private individuals. Antabio is developing inhibitors of bacterial metalloenzymes...